Shengjiang Powder alleviates oxidative stress damage and fibrosis in mice with atherosclerosis concurrent with non-alcoholic fatty liver disease
Treatment with "Shengjiang Powder," a representative formula for "simultaneous treatment of liver and heart," can slow the progression of atherosclerosis and concurrent NAFLD. The dosage shows a positive correlation with efficacy, and this effect is related to the regulation of liver oxidative stress and inflammation-induced fibrosis pathways.
Authors
- Jia He (ORCID: https://orcid.org/0000-0002-2338-9501)
- Bo Fu (ORCID: https://orcid.org/0000-0002-0310-2075)
- T.K. Wang (ORCID: https://orcid.org/0009-0009-9231-2637)
- Yan Zhang (ORCID: https://orcid.org/0000-0003-0998-5072)
- Bingjiu Lu
- Jingran Sun
Institutions
- Liaoning University of Traditional Chinese Medicine (CN)
- Affiliated Hospital of Liaoning University of Traditional Chinese Medicine (CN)
- Shenyang 242 Hospital (CN)
Publication Details
- Journal
- Hereditas
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s41065-025-00598-y
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00